Journal of Clinical Psychopharmacology最新文献

52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder. Centanafadine缓释治疗成人注意力缺陷/多动障碍52周的开放标签安全性和耐受性研究

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-02 DOI: 10.1097/JCP.0000000000002020

Gregory W Mattingly, Osman Turkoglu, Denise Chang, Caroline Ward, Taisa Skubiak, Zhen Zhang, Andrew J Cutler

{"title":"52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder.","authors":"Gregory W Mattingly, Osman Turkoglu, Denise Chang, Caroline Ward, Taisa Skubiak, Zhen Zhang, Andrew J Cutler","doi":"10.1097/JCP.0000000000002020","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002020","url":null,"abstract":"Background: Centanafadine (CTN) is a potential first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) currently in development for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. Safety, tolerability, and exploratory efficacy of CTN sustained release (SR) in adults were assessed over 52 weeks.Methods: Adults were enrolled after completing a phase 3 pivotal trial or de novo. The monitoring schedule employed a screening (up to 28 d for de novo group only), 52-week open-label, and 10-day safety follow-up periods. Participants received CTN SR 400 mg total daily dose, twice daily. Safety assessments included treatment-emergent adverse events (TEAEs), clinical laboratories, vital signs, electrocardiogram measures, the Study Medication Withdrawal Questionnaire, and the Columbia-Suicide Severity Rating Scale. Exploratory efficacy was assessed using the Adult Investigator Symptom Rating Scale (AISRS) and the Clinical Global Impression of Severity (CGI-S). Safety was analyzed with a mixed-effect model; efficacy was reported using summary statistics.Results: Of 662 adults enrolled [mean (SD) age, 36.7 (10.1) y; 51.1% female; 82.9% white], 653 received CTN SR, and 345 completed the trial. Altogether, 61.4% reported ≥1 TEAE, mostly mild or moderate in severity; insomnia (8.0%), nausea (7.7%), diarrhea and headache (7.0% each) were most common. Eighty (12.3%) discontinued because of TEAEs. Serious adverse events occurred in 12 (1.8%) participants; none were CTN SR-related per investigators. AISRS total scores improved up to 57% and CGI-S by 1.5 points from baseline.Conclusions: Results from this trial demonstrate that CTN SR 400 mg is safe and effective for long-term treatment of adults with ADHD.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weekly Changes in the Clozapine Concentration-to-Dose Ratio During Clozapine Titration in Japanese Patients With Schizophrenia. 日本精神分裂症患者氯氮平滴定期间氯氮平浓度剂量比的每周变化。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-07 DOI: 10.1097/JCP.0000000000002003

Yuki Kikuchi, Mutsumi Sakata, Kazuro Ikawa, Daisuke Kume, Naoki Horikawa, Hiroshi Komatsu, Hiroaki Tomita

{"title":"Weekly Changes in the Clozapine Concentration-to-Dose Ratio During Clozapine Titration in Japanese Patients With Schizophrenia.","authors":"Yuki Kikuchi, Mutsumi Sakata, Kazuro Ikawa, Daisuke Kume, Naoki Horikawa, Hiroshi Komatsu, Hiroaki Tomita","doi":"10.1097/JCP.0000000000002003","DOIUrl":"10.1097/JCP.0000000000002003","url":null,"abstract":"Background: To prevent inflammatory side effects early in the titration phase of clozapine, international guidelines recommend measuring clozapine blood levels weekly. However, data on such measurements are lacking.Methods: We retrospectively reviewed the medical records of all patients with schizophrenia who were treated with clozapine for the first time and whose clozapine blood levels were measured for at least 2 consecutive weeks from clozapine initiation at our institution from 2020 to 2024. Patients were divided into 2 groups based on whether they had a fever during the first 6 weeks of clozapine treatment. The clozapine concentration-to-dose (C/D) ratios were compared weekly within 6 weeks after starting clozapine.Results: A total of 28 patients were included in the study, of whom 6 developed a fever and 22 did not. The median C/D ratios in weeks 1 and 2 were significantly higher in patients with a fever than in those without (week 1: 2.12 vs 1.31, P = 0.0217; week 2: 3.48 vs 1.23, P = 0.01). There was no significant difference in C/D ratios between the groups from week 3 to week 6. During the first 6 weeks of treatment, C/D ratios increased markedly and showed peaks in patients with fever but remained stable in patients without fever.Conclusions: Measuring clozapine blood levels early in the titration phase helps estimate the metabolic capacity of patients. Furthermore, it is essential to pay attention to inflammation, which may increase clozapine C/D ratios.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"345-348"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pisa Syndrome After Discontinuation of Low-Dose Sulpiride: A Case Report. 停用小剂量舒必利后的比萨综合征1例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 DOI: 10.1097/JCP.0000000000002044

Genki Koyama, Masaki Nakano, Taketo Takata, Yu Mimura, Hiroyuki Uchida, Michitaka Funayama

引用次数: 0

Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions. Lumateperone治疗重度抑郁症和双相抑郁症的混合特征：推进治疗或提出新问题。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-30 DOI: 10.1097/JCP.0000000000002018

Soumya Surekha, Ashish Kumar Lamiyan, Pankaj Khatri, Amol N Patil

引用次数: 0

Use of Risperidone Long-Acting Injection in the Treatment of Anorexia Nervosa: A Case Report. 长效注射利培酮治疗神经性厌食症1例。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1097/JCP.0000000000001984

Ash Moradi, Emma Gill

引用次数: 0

The Role of Methylphenidate and Aripiprazole in the Treatment of Emotion Dysregulation in Children With ADHD. 哌醋甲酯与阿立哌唑治疗多动症儿童情绪失调的作用。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-16 DOI: 10.1097/JCP.0000000000002002

Pei-Yin Pan, Chin-Bin Yeh

{"title":"The Role of Methylphenidate and Aripiprazole in the Treatment of Emotion Dysregulation in Children With ADHD.","authors":"Pei-Yin Pan, Chin-Bin Yeh","doi":"10.1097/JCP.0000000000002002","DOIUrl":"10.1097/JCP.0000000000002002","url":null,"abstract":"Purpose: In this study, we examined the effectiveness of methylphenidate on emotion dysregulation among children with attention-deficit/hyperactivity disorder (ADHD), and the strategy of switching to or adding aripiprazole for nonresponders.Methods: We conducted a 3-step, 10-week, open-label trial including children (6-18 years old) with ADHD and emotion dysregulation, defined according to the Child Behavior Checklist-Dysregulation Profile. In step 1, patients received methylphenidate treatment for 4 weeks. In step 2, nonresponders were started on aripiprazole treatment for 4 weeks. Nonresponders in step 2 entered step 3, receiving a combination of methylphenidate and aripiprazole for 2 weeks. The primary outcome was the change from baseline in emotion dysregulation, assessed using the irritability subscale of the Aberrant Behavior Checklist. Secondary outcomes included the change from baseline in ADHD symptoms, cross-domain-associated symptoms, adaptive functioning, and neurocognitive profiles.Results: Among the 30 enrolled patients, 22 (73.3%) responded to methylphenidate (group MR), while 8 entered step 2 (aripiprazole treatment for methylphenidate nonresponders; group MN). In step 2, 5 patients responded to aripiprazole, while 2 patients entered step 3 and received methylphenidate plus aripiprazole. Patients who responded to methylphenidate or aripiprazole exhibited significant improvements in emotion dysregulation (Hedges' g: 2.62 and 1.30, respectively) and school adaptation. Emotion dysregulation severity was correlated with oppositional defiant disorder symptoms, but not with core symptoms of ADHD.Conclusions: The nature of emotion dysregulation in ADHD is heterogeneous regarding the response to methylphenidate. For most patients, methylphenidate significantly improved emotion dysregulation. Aripiprazole could be effective and safe for methylphenidate nonresponders.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"356-363"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review. 以智力残疾和罕见遗传变异为背景的精神分裂症患者氯氮平的使用：回顾性图表回顾。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-07 DOI: 10.1097/JCP.0000000000002000

Mark A Colijn

{"title":"Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review.","authors":"Mark A Colijn","doi":"10.1097/JCP.0000000000002000","DOIUrl":"10.1097/JCP.0000000000002000","url":null,"abstract":"Background: Treatment resistance in schizophrenia is associated with both intellectual disability and rare genetic variation. Information pertaining to the use of clozapine in this context has primarily come from case reports and small case series. Given the frequent occurrence of comorbid medical issues in various genetic disorders and the heightened sensitivity to antipsychotic medications among intellectually disabled individuals, additional information regarding the effectiveness and tolerability of clozapine in this population is needed, particularly in light of its unique side effect profile.Methods: This retrospective review of 1200 charts, which took place at a subspecialty psychiatry clinic, sought to characterize the use of clozapine in individuals with schizophrenia (or psychotic symptoms, generally speaking) and intellectual disability occurring on the background of rare genetic variation, a difficult to study and underserved patient population.Results: Twelve hundred charts were reviewed and 10 eligible individuals were identified, all of whom had been prescribed clozapine and carried a diagnosis of schizophrenia on the background of intellectual disability and rare genetic variation. Six of these 10 individuals harbored presumed pathogenic variants.Implications: This study affirms what is known about clozapine treatment in 22q11.2 deletion syndrome, adds to the scarce literature on Usher syndrome in this context, and provides the first accounts of clozapine use in 22q11.2 microduplication syndrome and DCX variant-related heterotopia.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"329-335"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders. 一项确定药物反应家族史是否能预测情绪障碍预后的系统综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1097/JCP.0000000000002011

Jeffrey J Rakofsky, Michael J Lucido, Boadie W Dunlop

{"title":"A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders.","authors":"Jeffrey J Rakofsky, Michael J Lucido, Boadie W Dunlop","doi":"10.1097/JCP.0000000000002011","DOIUrl":"10.1097/JCP.0000000000002011","url":null,"abstract":"Purpose/background: Examining a patient's family history of medication response is a commonly used method to inform treatment selection. Though widely recommended, there are no published reviews that assess the validity of this approach when treating patients with affective disorders.Methods/procedures: All published studies in the form of case-control or randomized controlled trials that enrolled probands with either bipolar I or II depression or major depression and were written in English were included. Studies must have also included biological relatives and must have included at least 2 families. The authors compared the methodology of each trial to a hierarchy of study designs best suited to demonstrate the predictive ability of a family history of response to a medication.Findings/results: All studies involved only a small number of participants and none of the publications included in this review used a study design that reached the highest level of study quality needed to prove the link between 2 family members' likelihood of response to a medicine. Two studies had some elements of a level I study while the remaining studies were classified at level II or III of the study hierarchy.Implications/conclusions: Although small studies suggest that a family history of drug response can predict outcome in mood disorder patients, the designs of these studies do not confirm this in a definitive manner.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"364-371"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a Clozapine Titration Monitoring Algorithm: Integration of Evidence and Clinical Experience at a University Hospital. 开发氯氮平滴定监测算法：证据与临床经验在某大学医院的整合。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-06-09 DOI: 10.1097/JCP.0000000000002033

Emre Mutlu, Elçin Özçelik Eroğlu, M İrem Yildiz, Doğukan Koçyiğit, Aygün Ertuğrul, A Elif Anil Yağcioğlu

引用次数: 0

Exploring the Addictive Potential of Tranylcypromine: A Case Report. 探索三酰环丙胺的成瘾性：一个病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-07 DOI: 10.1097/JCP.0000000000001998

Livia Beraldo de Lima, Laura Fernandes Berto, Victor Hugo Spitz, João P De Aquino, Rodolfo Furlan Damiano

引用次数: 0